AKT3 is altered in 1.27% of malignant glioma patients [2].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

APC is altered in 3.53% of malignant glioma patients [2].

APC is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains APC status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

BRAF is altered in 4.41% of malignant glioma patients [2].

BRAF is an inclusion eligibility criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain BRAF status and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

CCND1 is altered in 1.02% of malignant glioma patients [2].

CCND1 is an inclusion eligibility criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain CCND1 status and malignant glioma as inclusion criteria, 2 are early phase 1 (2 open) [3].

CCND2 is altered in 2.19% of malignant glioma patients [2].

CCND2 is an inclusion eligibility criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain CCND2 status and malignant glioma as inclusion criteria, 2 are early phase 1 (2 open) [3].

CDK4 is altered in 9.22% of malignant glioma patients [2].

CDK4 is an inclusion eligibility criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain CDK4 status and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) [3].

CDK6 is altered in 1.49% of malignant glioma patients [2].

CDK6 is an inclusion eligibility criterion in 4 clinical trials for malignant glioma, of which 4 are open and 0 are closed. Of the trials that contain CDK6 status and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) and 1 is phase 1 (1 open) [3].

CDKN2A is altered in 30.73% of malignant glioma patients [2].

CDKN2A is an inclusion eligibility criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain CDKN2A status and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) [3].

CDKN2B is altered in 32.1% of malignant glioma patients [2].

CDKN2B is an inclusion eligibility criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain CDKN2B status and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) [3].

CDKN2C is altered in 3.88% of malignant glioma patients [2].

CDKN2C is an inclusion eligibility criterion in 3 clinical trials for malignant glioma, of which 3 are open and 0 are closed. Of the trials that contain CDKN2C status and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) [3].

CTDNEP1 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains CTDNEP1 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CTNNB1 is altered in 0.96% of malignant glioma patients [2].

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

DDX3X is altered in 0.37% of malignant glioma patients [2].

DDX3X is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is altered in 26.34% of malignant glioma patients [2].

EGFR is an inclusion eligibility criterion in 6 clinical trials for malignant glioma, of which 4 are open and 2 are closed. Of the trials that contain EGFR status and malignant glioma as inclusion criteria, 4 are phase 1 (4 open) and 2 are phase 1/phase 2 (0 open) [3].

EPHA2 is altered in 1.79% of malignant glioma patients [2].

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERBB2 is altered in 1.71% of malignant glioma patients [2].

ERBB2 is an inclusion eligibility criterion in 2 clinical trials for malignant glioma, of which 1 is open and 1 is closed. Of the trials that contain ERBB2 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

ERBB4 is altered in 2.3% of malignant glioma patients [2].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 0 are open and 1 is closed. Of the trial that contains ERBB4 status and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FGFR1 is altered in 4.05% of malignant glioma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

FGFR3 is altered in 3.51% of malignant glioma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

GLI2 is altered in 3.15% of malignant glioma patients [2].

GLI2 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains GLI2 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A is altered in 3.95% of malignant glioma patients [2].

H3F3A is an inclusion eligibility criterion in 4 clinical trials for malignant glioma, of which 4 are open and 0 are closed. Of the trials that contain H3F3A status and malignant glioma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [3].

IDH1 is altered in 19.88% of malignant glioma patients [2].

IDH1 is an inclusion eligibility criterion in 5 clinical trials for malignant glioma, of which 5 are open and 0 are closed. Of the trials that contain IDH1 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

IDH2 is altered in 1.92% of malignant glioma patients [2].

IDH2 is an inclusion eligibility criterion in 5 clinical trials for malignant glioma, of which 5 are open and 0 are closed. Of the trials that contain IDH2 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

KDM6A is altered in 2.13% of malignant glioma patients [2].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KIT is altered in 5.59% of malignant glioma patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2C is altered in 4.1% of malignant glioma patients [2].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2D is altered in 8.08% of malignant glioma patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP1B is altered in 3.48% of malignant glioma patients [2].

LRP1B is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is altered in 4.43% of malignant glioma patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH1 is altered in 1.99% of malignant glioma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH2 is altered in 3.3% of malignant glioma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH6 is altered in 3.83% of malignant glioma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MTOR is altered in 3.47% of malignant glioma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

MYC is altered in 1.61% of malignant glioma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCL is altered in 1.03% of malignant glioma patients [2].

MYCL is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains MYCL status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is altered in 2.32% of malignant glioma patients [2].

MYCN is an inclusion eligibility criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain MYCN status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

NF1 is altered in 17.4% of malignant glioma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and malignant glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NTRK1 is altered in 2.07% of malignant glioma patients [2].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

NTRK2 is altered in 1.49% of malignant glioma patients [2].

NTRK2 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains NTRK2 status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

NTRK3 is altered in 1.49% of malignant glioma patients [2].

NTRK3 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains NTRK3 status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

OTX2 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains OTX2 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFA is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFA status and malignant glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFB is altered in 0.33% of malignant glioma patients [2].

PDGFB is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFB status and malignant glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 9.64% of malignant glioma patients [2].

PDGFRA is an inclusion eligibility criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

PDGFRB is altered in 2.63% of malignant glioma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and malignant glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3C2B is altered in 6.86% of malignant glioma patients [2].

PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3C2B status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

PIK3CA is altered in 12.32% of malignant glioma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

PIK3R1 is altered in 9.16% of malignant glioma patients [2].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

PMS2 is altered in 1.81% of malignant glioma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPM1D is altered in 2.13% of malignant glioma patients [2].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTCH1 is altered in 3.57% of malignant glioma patients [2].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is altered in 29.52% of malignant glioma patients [2].

PTEN is an inclusion eligibility criterion in 2 clinical trials for malignant glioma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [3].

PVT1 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PVT1 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RELA is altered in 1.47% of malignant glioma patients [2].

RELA is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains RELA status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SHH is altered in 0.53% of malignant glioma patients [2].

SHH is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains SHH status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 is altered in 3.73% of malignant glioma patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMO is altered in 2.03% of malignant glioma patients [2].

SMO is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SNCAIP is altered in 1.71% of malignant glioma patients [2].

SNCAIP is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains SNCAIP status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SUFU is altered in 1.45% of malignant glioma patients [2].

SUFU is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains SUFU status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

TACC3 is altered in 1.49% of malignant glioma patients [2].

TACC3 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains TACC3 status and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [3].

TERT is altered in 4.23% of malignant glioma patients [2].

TERT is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains TERT status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 39.21% of malignant glioma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

YAP1 is altered in 2.78% of malignant glioma patients [2].

YAP1 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains YAP1 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].

ZMYM3 is altered in 2.77% of malignant glioma patients [2].

ZMYM3 is an inclusion eligibility criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains ZMYM3 status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [3].